Page last updated: 2024-08-21

alpha-aminopyridine and Dermatitis Medicamentosa

alpha-aminopyridine has been researched along with Dermatitis Medicamentosa in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (12.50)	18.7374
1990's	5 (62.50)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (12.50)	24.3611
2020's	1 (12.50)	2.80

Authors

Authors	Studies
Abida, W; Brownstein, S; Drilon, A; Gounder, MM; Groover, A; Harding, JJ; Hyman, DM; Janku, F; Lacouture, ME; Lezcano, C; Li, BT; Liu, D; Offin, M; Sullivan, RJ; Torrisi, JM; Varterasian, M; Welsch, D; Wu, J	1
Arteaga, CL; Awada, A; Baselga, J; Campone, M; Chia, S; Clemons, M; Cortés, J; De Laurentiis, M; Dharan, B; Di Tomaso, E; Hachemi, S; Hurvitz, S; Im, SA; Ito, Y; Iwata, H; Jagiełło-Gruszfeld, A; Jiang, Z; Jonat, W; Massacesi, C; Masuda, N; Pistilli, B; Takahashi, M; Tseng, LM; Urban, P; Vuylsteke, P	1
Aihara, M; Hariya, T; Ikezawa, Z; Kitamura, K; Nakajima, H; Osawa, J	1
Hayakawa, R; Osada, T; Sugiura, M	1
Forney, RB; Griffis, LC	1
Aris, K; Hayakawa, R; Matsunaga, K; Ogino, Y	1
Kabasawa, Y; Kanzaki, T	1
Kawashima, M; Yamashita, H	1

Reviews

1 review(s) available for alpha-aminopyridine and Dermatitis Medicamentosa

Article	Year
Fixed drug eruption due to amlexanox. Contact dermatitis, 1998, Volume: 38, Issue:2 Topics: Adult; Aged; Aminopyridines; Anti-Allergic Agents; Drug Eruptions; Erythema; Female; Humans; Male; Middle Aged; Patch Tests; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal	1998

Trials

2 trial(s) available for alpha-aminopyridine and Dermatitis Medicamentosa

Article	Year
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers. Investigational new drugs, 2021, Volume: 39, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Analgesics; Anti-Bacterial Agents; Antineoplastic Agents; Drug Eruptions; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Skin; Steroids; Young Adult	2021
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 2017, Volume: 18, Issue:7 Topics: Aged; Alanine Transaminase; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Double-Blind Method; Drug Eruptions; Estradiol; Exanthema; Female; Fulvestrant; Humans; Hyperglycemia; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Retreatment; Signal Transduction; Survival Rate	2017

Article

Year

Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers.

Investigational new drugs, 2021, Volume: 39, Issue:3

Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Analgesics; Anti-Bacterial Agents; Antineoplastic Agents; Drug Eruptions; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Skin; Steroids; Young Adult

2021

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet. Oncology, 2017, Volume: 18, Issue:7

Topics: Aged; Alanine Transaminase; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Double-Blind Method; Drug Eruptions; Estradiol; Exanthema; Female; Fulvestrant; Humans; Hyperglycemia; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Retreatment; Signal Transduction; Survival Rate

2017

Other Studies

5 other study(ies) available for alpha-aminopyridine and Dermatitis Medicamentosa

Article	Year
Allergenicity and tolerogenicity of amlexanox in the guinea pig. Contact dermatitis, 1994, Volume: 31, Issue:1 Topics: Administration, Oral; Administration, Topical; Allergens; Aminopyridines; Animals; Anti-Inflammatory Agents; Dermatitis, Allergic Contact; Drug Eruptions; Drug Hypersensitivity; Female; Guinea Pigs; Immunization; Patch Tests	1994
The acute toxicity of 2-benzylaminopyridine. Toxicology and applied pharmacology, 1976, Volume: 38, Issue:3 Topics: Administration, Oral; Administration, Topical; Aminopyridines; Animals; Drug Eruptions; Ethanol; Guinea Pigs; Half-Life; Injections, Intraperitoneal; Lethal Dose 50; Male; Mice; Pyridines; Sleep; Time Factors	1976
Systemic contact dermatitis due to amlexanox. Contact dermatitis, 1992, Volume: 27, Issue:2 Topics: Adult; Aminopyridines; Dermatitis, Contact; Drug Eruptions; Female; Humans; Ophthalmic Solutions	1992
Allergic contact dermatitis from amlexanox (Elics) ophthalmic solution. Contact dermatitis, 1991, Volume: 24, Issue:2 Topics: Aged; Aminopyridines; Dermatitis, Contact; Drug Eruptions; Female; Humans; Male; Ophthalmic Solutions; SRS-A	1991
Contact dermatitis from amlexanox eyedrops. Contact dermatitis, 1991, Volume: 25, Issue:4 Topics: Administration, Topical; Adult; Aminopyridines; Dermatitis, Contact; Drug Eruptions; Eyelids; Facial Dermatoses; Female; Humans; Male; Middle Aged; Ophthalmic Solutions; Patch Tests	1991